Table of Contents
Optimal management of metastatic colorectal cancer with the anti-EGFR monoclonal antibodies
| Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer | |
| M. Fakih, R. Wong |
| Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer | |
| M. Fakih, M. Vincent |
| KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies | |
| D. Soulières, W. Greer, Anthony M. Magliocco, D. Huntsman, S. Young, M.-S. Tsao, S. Kamel-Reid |
Copyright © 2012 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)